Apr 2020
Conyers provided Cayman Islands legal advice to BBI Life Sciences Corporation (“BBI Life Sciences”) in its HK$1.96 billion privatisation by way of a scheme of arrangement between the company and its scheme shareholders pursuant to an offer by LJ Future Ltd. and the delisting of BBI Life Sciences from the Hong Kong Stock Exchange.
BBI Life Sciences operates in the life sciences research products and services industry. It provides laboratory services and products to hospitals, pharmaceutical and biotech companies, government testing and diagnostics centres, and distributors in China and overseas.
Partner Bernadette Chen of Conyers’ Hong Kong office and Ben Hobden of Conyers’ Cayman Islands office advised on the matter working alongside Norton Rose Fulbright.